Daraxonrasib Halves Death Risk in Previously Treated Pancreatic Cancer

RASolute 302 provides the first randomized phase 3 evidence that a RAS(ON) multiselective inhibitor outperforms standard second-line chemotherapy in RAS-mutated metastatic pancreatic cancer, introducing an oral targeted option with a manageable, non-hematologic toxicity profile.

📅 Journal publication: Jul 23, 2026 (online May 31, 2026) · Last updated: Aug 26, 2026

daraxonrasibRMC-6236RAS(ON) inhibitorKRAStargeted therapymetastatic pancreatic cancermPDACsecond-line therapyphase 3RASolute 302overall survivalPFS Oncology Pharmacy

Background Information

Daraxonrasib doubles survival in metastatic pancreatic cancer.

Metastatic pancreatic ductal adenocarcinoma (mPDAC) has limited treatment options, and new therapies like daraxonrasib could improve outcomes. In patients with mPDAC, daraxonrasib achieved a median overall survival of 13.2 months versus 6.6 months with chemotherapy; hazard ratio was 0.40 (P<0.001). Daraxonrasib significantly improves survival and progression outcomes in patients with RAS mutations in mPDAC, with fewer severe adverse events leading to discontinuation compared to chemotherapy. Daraxonrasib offers a survival advantage over chemotherapy in previously treated mPDAC patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM, RASolute 302 Trial Investigators

Citation: O'Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. The New England journal of medicine. 2026;395(4):325-337. doi:10.1056/NEJMoa2605555

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →